))
Episode 45: FDA Actions on Kratom and 7-Hydroxymitragynine (7-OH)
Manage episode 498471317 series 3649261
Content provided by KGK Science. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by KGK Science or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
The FDA is sounding the alarm. In a major regulatory move, the agency is recommending that 7-hydroxymitragynine (7-OH)—a potent synthetic derivative of kratom—be scheduled under the Controlled Substances Act. Why? Because this lab-created version of kratom’s active compound is up to 500% more potent than its natural form and is increasingly tied to severe health risks, including liver toxicity, seizures, substance use disorder, and even death.
In this episode, we break down:
- The FDA and DEA's joint stance on synthetic kratom
- The gray zone of regulation and enforcement
- Public health concerns and the real-world impact of high-dose 7-OH products
- The urgent need for research into kratom’s abuse potential and therapeutic value
As the debate around kratom heats up, this episode helps you stay informed on one of the most controversial substances in the supplement space.
48 episodes
Share
